The Journal of Urology
Volume 180, Issue 3 , Pages 830-835 , September 2008

Association of Gadolinium Based Magnetic Resonance Imaging Contrast Agents and Nephrogenic Systemic Fibrosis

  • Gautam Bhave

      Affiliations

    • Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee
    • Nothing to disclose.
    • ,
  • Julia B. Lewis

      Affiliations

    • Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee
    • Nothing to disclose.
    • ,
  • Sam S. Chang

      Affiliations

    • Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
    • Corresponding Author InformationCorrespondence: Department of Urologic Surgery, A-1302 Medical Center North, Vanderbilt University Medical Center, Nashville, Tennessee 37232 (telephone: 615-322-2101; FAX: 615-322-8990).
    • Financial interest and/or other relationship with Sanofi-Aventis, Tetralogic, Indevus, Bioniche and Amgen.

Received 1 December 2007

References 

  1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000
  2. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;23:383
  3. DeHoratius DM, Cowper SE. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial. 2006;19:191
  4. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int. 2007;72:260
  5. Swaminathan S, Shah SV. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol. 2007;18:2636
  6. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol. 2003;139:903
  7. Cassis TB, Jackson JM, Sonnier GB, Callen JP. Nephrogenic fibrosing dermopathy in a patient with acute renal failure never requiring dialysis. Int J Dermatol. 2006;45:56
  8. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol. 2003;48:55
  9. Swartz RD, Crofford LJ, Phan SH, Ike RW, Su LD. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563
  10. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website], 2001–2007Cowper SE. http://www.icnfdr.orgAccessed October 24, 2007
  11. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148
  12. U.S. Food and Drug Administration: Information for Healthcare Professionals: Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging Scans. http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200612HCP.htm2006;Accessed October 24, 2007
  13. Pharmacovigilance Working Party: Increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. http://www.ismrm.org/special/MHRA_Report.pdf2007;Accessed November 18, 2007
  14. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006;21:1104
  15. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586
  16. Cheng S, Abramova L, Saab G, Turabelidze G, Patel P, Arduino M, et al. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep. 2007;56:137
  17. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359
  18. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264
  19. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant. 2007;7:2425
  20. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168
  21. Frost and Sullivan: North American MRI Contrast Media Market. Nashville, TN: Frost and Sullivan, Vanderbilt University Walker Library; 2007;http://www.frost.comPublished June 25, Accessed November 2, 2007
  22. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. 2007;22:3174
  23. Goyen M, Ruehm SG, Debatin JF. MR-angiography: the role of contrast agents. Eur J Radiol. 2000;34:247
  24. U.S. Food and Drug Administration: Information for Healthcare Professionals: Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging. http://www.fda.gov/cder/drug/InfoSheets/HCP/gcca_200705.htm2007;Accessed October 24, 2007
  25. Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563
  26. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5:491
  27. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol. 2007;80:73
  28. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27
  29. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21
  30. Runge VM, Knopp MV. Off-label use and reimbursement of contrast media in MR. J Magn Reson Imaging. 1999;10:489
  31. Hayes E. Bracco reports case of NSF with gadolinium contrast agent ProHance (Diagnostic Imaging). http://www.dimag.com/showNews.jhtml?articleID=2018020912007;Accessed November 18, 2007
  32. Goveia M, Chan BP, Patel PR. Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;57:725
  33. Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med. 2007;357:720
  34. Okada S, Katagiri K, Kumazaki T, Yokoyama H. Safety of gadolinium contrast agent in hemodialysis patients. Acta Radiol. 2001;42:339
  35. Broome DR, Cottrell AC, Kanal E. Response to “Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?”. AJR Am J Roentgenol. 2007;189:W234
  36. Kanal E, Barkovich AJ, Bell C, Borgstede JP, Bradley WG, Froelich JW, et al. ACR guidance document for safe MR practices: 2007. AJR Am J Roentgenol. 2007;188:1447
  37. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44:1393
  38. Barrett BJ, Parfrey PS. Clinical practice (Preventing nephropathy induced by contrast medium). N Engl J Med. 2006;354:379
  39. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004;291:2328
  40. Finn WF. The clinical and renal consequences of contrast-induced nephropathy. Nephrol Dial Transplant. 2006;21:i2
  41. Israel GM, Bosniak MA. Renal imaging for diagnosis and staging of renal cell carcinoma. Urol Clin North Am. 2003;30:499
  42. Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005;236:441
  43. Maturen KE, Nghiem HV, Caoili EM, Higgins EG, Wolf JS, Wood DP. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007;188:563

 Editor's Note: This article is the first of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 1196 and 1197.

PII: S0022-5347(08)01225-1

doi: 10.1016/j.juro.2008.05.005

The Journal of Urology
Volume 180, Issue 3 , Pages 830-835 , September 2008

Article Tools

* Image Usage & Resolution